Federal contractor · DURHAM, NC

MUCOMMUNE LLC

No contract obligations recorded for MUCOMMUNE LLC in FY2026. Since FY2025: $306.2K. Its largest customer was National Institutes of Health ($0). It also received $9.2M in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
1
Sole-source
—
Single offer
—
UEI
NWVPL2L4JMN8
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 306.2KFY2025
  2. 0FY2026

Top buying agencies

Obligations in FY2026.

  1. National Institutes of Health$00.0%
    1 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Largest awards

  1. SUSTAINED RELEASE OF VRC07 FROM CAPSULE-INTRAVAGINAL RING FOR PREVENTING HIV TRANSMISSION$306.2K
    National Institutes of Health· Orange County, NC· Research & development· Jun 24, 2025 – Jul 16, 2026· 75N93025C00021

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

MUCOMMUNE LLC received $9.2M in federal assistance in FY2026, on 21 actions (3 new awards), +52% vs FY2025. Its largest program was 93.865 · Child Health and Human Development Extramural Research ($4.7M).

Assistance · FY2026
$9.2M
New awards
3
Actions
21
Since FY2021
$27.6M

Assistance by fiscal year

  1. 4MFY2021
  2. 4.1MFY2022
  3. 2.9MFY2023
  4. 1.3MFY2024
  5. 6.1MFY2025
  6. 9.2MFY2026

By type

  1. Grants$9.2M100%

Top programs

  1. 93.865 · Child Health and Human Development Extramural Research$4.7M51%
  2. 93.855 · Allergy and Infectious Diseases Research$2.3M25%
  3. 93.395 · Cancer Treatment Research$2.2M24%

Awarding agencies

  1. National Institutes of Health$9.2M100%
    Department of Health and Human Services

Largest awards

  1. SBIR: IN VIVO VALIDATION AND IND-ENABLING DEVELOPMENT OF MM004, A BISPECIFIC INHALED IMMUNOTHERAPY FOR RSV AND MPV - PROJECT SUMMARY…$2.4M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Mar 4, 2021 – Jun 30, 2026· R44AI157661
  2. FAST DISSOLVING MM008 TABLET FOR INSTANT ON-DEMAND NON-HORMONAL CONTRACEPTION - PROJECT SUMMARY NEARLY HALF OF ALL PREGNANCIES IN THE U.S…$2.3M
    93.865 · Child Health and Human Development Extramural Research· National Institutes of Health· Project grant· Sep 12, 2025 – Sep 4, 2026· R44HD118898
  3. SBIR: IN VIVO ENGINEERING OF MULTIFACETED B7H3.CAR-T CELLS FOR CELLULAR IMMUNOTHERAPY OF PANCREATIC DUCTAL ADENOCARCINOMA - PROJECT SUMMARY…$2.3M
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Sep 15, 2025 – Aug 13, 2026· R44CA310402
  4. IND?ENABLING DEVELOPMENT OF MM?008 IVR, AN ANTIBODY-BASED NONHORMONAL CONTRACEPTIVE INTRAVAGINAL RING - SUMMARY NEARLY HALF OF ALL…$2.1M
    93.865 · Child Health and Human Development Extramural Research· National Institutes of Health· Project grant· Sep 19, 2022 – Mar 4, 2026· R44HD107824
  5. SBIR: IN VIVO ENGINEERING OF B7-H3.CAR-T CELLS FOR OVARIAN CANCER THERAPY - PROJECT SUMMARY T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR…$2.1M
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Sep 10, 2025 – Aug 26, 2026· R44CA306674
  6. IND-ENABLING DEVELOPMENT OF MM-009, A RESERVOIR-INTRAVAGINAL RING FOR ULTRA-HIGHRATES OF MONTH-LONG LACTIC ACID RELEASE TO TREAT AND…$2M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Jun 23, 2025 – May 26, 2026· R44AI192170

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Subawards

Matched by Unique Entity ID: the first-tier subawards this organization reported as a prime recipient, and those primes reported paying it.

As a prime: who it pays · FY2026

No subawards reported as a prime in FY2026.

As a sub-recipient: who pays it · FY2026

No subawards reported to it in FY2026.

By fiscal year

  • FY2021: $456.4K paid out · $35.4K received
  • FY2022: $1.1M paid out · $0 received
  • FY2023: $98.1K paid out · $0 received
  • FY2025: $1.3M paid out · $0 received

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 8, 2026, loaded Oct 8, 2026 · Subawards loaded from FY2021.

Teaming partners

Companies this company reported paying, primes that reported paying it, from FFATA subaward reports.

Companies it pays

7 companies · $3M reported

  1. UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL$1.5M
    CHAPEL HILL, NC · 7 subawards
  2. UNIVERSITY OF LOUISIANA AT LAFAYETTE$683.7K
    LAFAYETTE, LA · 3 subawards
  3. UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON$543.3K
    GALVESTON, TX · 3 subawards

Primes that pay it

1 company · $35.4K reported

  1. TRUSTEES OF BOSTON UNIVERSITY$35.4K
    BOSTON, MA · 1 subaward

Showing the top 3 of each list. Open the profile for potential partners and the full lists.

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 8, 2026, loaded Oct 8, 2026 · Subawards loaded from 2021.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. FOX CHASE CHEMICAL DIVERSITY CENTER INC.$306.5K−100% in FY2026
    DOYLESTOWN, PA · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. IMMPORT THERAPEUTICS INC$300K
    IRVINE, CA · 98% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. BASE PAIR BIOTECHNOLOGIES INC$300K
    PEARLAND, TX · 98% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026.